748 related articles for article (PubMed ID: 26681984)
1. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
2. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
3. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
5. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
6. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
8. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
9. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
11. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
13. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
14. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Pereira Mestre R; Treglia G; Ferrari M; Pascale M; Mazzara C; Azinwi NC; Llado' A; Stathis A; Giovanella L; Roggero E
Eur J Clin Invest; 2019 Mar; 49(3):e13063. PubMed ID: 30580449
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
16. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
18. Lutetium
Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
[TBL] [Abstract][Full Text] [Related]
19. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
20. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]